Long-term outcomes of concurrent chemo-proton therapy for unresectable stage III non-small cell lung cancer: a Japanese national registry study
CCPT for unresectable stage III NSCLC is considered safe and effective. Definitive treatment was possible even in patients who were not eligible for photon thoracic radiotherapy.
Authors
- Hiromitsu Iwata
- Kimihiro Shimizu (ORCID: https://orcid.org/0000-0003-4076-5174)
- Kazushi Maruo (ORCID: https://orcid.org/0000-0002-3093-0386)
- Masatoshi Nakamura (ORCID: https://orcid.org/0009-0008-3329-5999)
- Masayuki Araya (ORCID: https://orcid.org/0000-0002-8529-5420)
- Masao Murakami (ORCID: https://orcid.org/0000-0001-9530-0337)
- Miyako Satouchi (ORCID: https://orcid.org/0000-0003-0613-9487)
- Hideyuki Harada
- Masaki Nakamura (ORCID: https://orcid.org/0000-0003-1859-2342)
- Hiroshi Taguchi (ORCID: https://orcid.org/0000-0003-2348-4071)
- Takayuki Hashimoto (ORCID: https://orcid.org/0000-0001-5276-3665)
- Takahiro Waki (ORCID: https://orcid.org/0000-0002-4037-1688)
- Kazuya Inoue (ORCID: https://orcid.org/0000-0003-4407-5162)
- Hitoshi Tatebe
Institutions
- Hokkaido University of Science (JP)
- Shinshu University (JP)
- University of Tsukuba (JP)
- Hokkaido University (JP)
- Tenri Hospital (JP)
- Shizuoka Cancer Center (JP)
- Fukui Prefectural Hospital (JP)
- Tsuyama Chuo Hospital (JP)
- Hokkaido University Hospital (JP)
- National Cancer Center Hospital East (JP)
- Nagoya Medical Center (JP)
- Aizawa Hospital (JP)
- Hyogo Prefectural Cancer Center (JP)
- Southern Tohoku General Hospital (JP)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1016/j.radonc.2025.111307
- Primary Topic
- Radiation Therapy and Dosimetry
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Hokkaido University
- Japan Society for the Promotion of Science